Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,216 Followers

AXSM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$75.56 - $139.13

Previous CloseN/A

Volume140.83K

Average Volume (3M)621.50K

Market Cap

$5.85B

Enterprise Value$5.08B

Total Cash (Recent Filing)$303.02M

Total Debt (Recent Filing)$215.29M

Price to Earnings (P/E)―

Beta1.00

Next Earnings

Nov 10, 2025

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding49,901,485

10 Day Avg. Volume491,430

30 Day Avg. Volume621,505

Financial Highlights & Ratios

PEG Ratio-1.03

Price to Book (P/B)71.10

Price to Sales (P/S)10.51

P/FCF Ratio-31.50

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue10.27

Enterprise Value/Gross Profit11.22

Enterprise Value/Ebitda-22.60

Forecast

1Y Price Target

$169.71

Price Target Upside43.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

EarningsAnalyst projects a significant increase in Auvelity's net product sales for the second quarter.

Market PerformanceAuvelity continues to ramp nicely and respond to the increased sales force.

Product RolloutSYMBRAVO's rollout is progressing with a field force of about 100 representatives and has secured a contract with one of the three largest group purchasing organizations for potential formulary coverage.

Bears Say

Growth ExpectationsSymbravo, AXSM's new migraine drug, is expected to have slow but steady and sustained growth.

Payer CoveragePayer coverage for SYMBRAVO is currently at approximately 38% of all lives covered, indicating room for improvement.

Prescription TrendsAuvelity prescriptions experienced a slight decline for the third consecutive week, with a 1% decrease in total and new prescriptions.

Axsome Therapeutics News

Axsome Therapeutics management to meet with Needham

Meeting to be held in New York on August 12 hosted by Needham. Published first on TheFly –...

13d ago

AXSM

Axsome Therapeutics price target raised to $176 from $173 at BofA

BofA raised the firm’s price target on Axsome Therapeutics (AXSM) to $176 from $173 and keeps a Buy...

19d ago

AXSM

Morning Movers: Wayfair surges following second quarter results

Stock futures rebounded strongly following last Friday’s steep selloff as investors digested a surprisingly weak July jobs report....

20d ago

Axsome Therapeutics reports Q2 EPS (97c), consensus ($1.09)

Reports Q2 revenue $150.042M, consensus $138.02M. “Axsome delivered robust second quarter performance, reflecting strong underlying demand for our...

20d ago

AXSM

Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target...

3d ago

AXSM

Axsome Therapeutics Receives Paragraph IV Certification Notice

The latest update is out from Axsome Therapeutics ( ($AXSM) ). On August 19, 2025, Axsome Therapeutics received...

3d ago

AXSM

Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Axsome Therapeutics, with a price target of...

17d ago

AXSM

Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics and keeping the price target...

17d ago

AXSM

Axsome Therapeutics’ Earnings Call Highlights Robust Growth

Axsome Therapeutics Inc. (($AXSM)) has held its Q2 earnings call. Read on for the main highlights of the...

18d ago

AXSM

Axsome Therapeutics Reports Strong Q2 2025 Growth

Axsome Therapeutics Inc. ( ($AXSM) ) has released its Q2 earnings. Here is a breakdown of the information...

19d ago

AXSM

Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman from...

19d ago

AXSM

Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy...

19d ago

AXSM

Strong Growth Prospects and Strategic Advancements Propel Axsome Therapeutics to ‘Buy’ Rating

Analyst Joseph Thome of TD Cowen maintained a Buy rating on Axsome Therapeutics, retaining the price target of...

19d ago

AXSM

Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Reinforce Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on AXSM stock, giving a Buy rating today....

20d ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc.’s price range in the past 12 months?

Axsome Therapeutics Inc. lowest stock price was $75.56 and its highest was $139.13 in the past 12 months.

What is Axsome Therapeutics Inc.’s market cap?

Axsome Therapeutics Inc.’s market cap is $5.85B.

When is Axsome Therapeutics Inc.’s upcoming earnings report date?

Axsome Therapeutics Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 78 days.

How were Axsome Therapeutics Inc.’s earnings last quarter?

Axsome Therapeutics Inc. released its earnings results on Aug 04, 2025. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.055 by $0.085.

Is Axsome Therapeutics Inc. overvalued?

According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc. pay dividends?

Axsome Therapeutics Inc. does not currently pay dividends.

What is Axsome Therapeutics Inc.’s EPS estimate?

Axsome Therapeutics Inc.’s EPS estimate is -0.83.

How many shares outstanding does Axsome Therapeutics Inc. have?

Axsome Therapeutics Inc. has 49,901,485 shares outstanding.

What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?

Axsome Therapeutics Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.055. Following the earnings report the stock price went up 3.417%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?

Currently, no hedge funds are holding shares in AXSM

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-280.68%

Trailing 12-Months

Asset Growth

16.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with significant revenue growth and successful product launches. However, the substantial net loss and challenges in market access for SYMBRAVO present areas for concern.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$169.71

▲(43.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","142":"$142","201":"$201","112.5":"$112.5","171.5":"$171.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$169.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$144.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,112.5,142,171.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,110.47999999999999,117.94,125.39999999999999,132.85999999999999,140.32,147.78,155.24,162.7,170.16,177.62,185.07999999999998,192.54,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,108.14999999999999,113.28,118.41,123.53999999999999,128.67000000000002,133.8,138.93,144.06,149.19,154.32,159.45,164.58,{"y":169.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.02,106.17230769230768,109.32461538461538,112.47692307692307,115.62923076923076,118.78153846153846,121.93384615384615,125.08615384615385,128.23846153846154,131.39076923076922,134.5430769230769,137.69538461538463,140.8476923076923,{"y":144,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >